PREVALENCE, CLINICAL COURSE OF POSTCAPILLAROTOXIC GLOMERULONEPHRITIS IN PRIBAIKALJE

Summary. Postcapillarotoxic glomerulonephritis (PKTGN) is the most frequent and serious complication of hemorrhagic vasculitis (HV). 2 ere are few studies devoted to the epidemiology of glomerulonephritis, associated with HV, and in the Pribaikalye the disease has not been investigated. We investigated the prevalence, clinical course of PKTGN patients in Pribaikalje. A high frequency of kidney lesions in HV have been revealed in the Baikalian region. Most o3 en hemorrhagic vasculitis and therefore his renal manifestations occurs in Buryat ethnic group of Pribaikalje. In the older patients more severe forms of glomerulonephritis are revealed, which are more di4 cult to predict. Key words: hemorrhagic vasculitis, glomerulonephritis, renal failure.›Œ’ˆ€€S‡…‘Œ„†…† ‹S„†‚™…ƒ (›•) ˆƒ“ˆ„…ƒ„’ † ‡Œ“Œ€S-™…˜ˆ‹S““Ž’ …’’‚““Ž’ ‹S„†‚™…ƒS’, “ˆ€S&S'*…’ “‚ƒ… ’…†€ˆ/…€†‚™’/…… †ˆ&…, ‹“‚ƒ€Œ““…— ˆ€‡S“ˆ‹, ‹†™'‘S’ “ˆ‘†… [2]. !ˆ€S&Œ“…Œ “ˆ‘Œ†, †S† “€S‹…™ˆ, ˆ“€Œ‰Œ™’Œƒ “€ˆ‡“ˆ˜ ˜Ssˆ™Œ‹S“…’, ’‹™’’„% “ˆƒŒ“/…S™%“ˆ ˆ“S„“Ž’ “€ˆ’‹™Œ“…Œ’ ›• [1, 7]. $Œƒ Œ‰…“ˆ‡ˆ ’“Œ“…’ ‹ ˆƒ“ˆ‘Œ-“…… ‘S„ƒˆƒŽ “ˆ€S&Œ“…’ “ˆ‘Œ† “€… ›•. 8‰“… S‹ƒˆ€Ž ‚†S˜Ž‹S'ƒ “S 20-70% [9, 16], S ‹ €’‰Œ “Ss™'‰Œ“…† “Œ-”€ˆ“Sƒ…’ sŽ™S ‹Ž’‹™Œ“S ‚ 85-100% sˆ™%“Ž— ›• [15]. • “ˆ„™Œ‰“…Œ ‡ˆ‰Ž ˆƒ’Œ‘SŒƒ„’ €ˆ„ƒ ˜Ssˆ™Œ‹SŒ’ˆ„ƒ… ›•, “Œ ‚’Œ“%‘SŒƒ„’ ‘S„ƒˆƒS ˜Ssˆ™Œ‹S“…’ „ “ˆ€S&Œ“…Œ’ “ˆ‘Œ†, €S˜‹…ƒ…Œ’ “ˆ„ƒ†S“…™™’€ˆƒˆ†„…‘Œ„†ˆ‡ˆ ‡™ˆ’Œ€‚™ˆ“Œ”-€…ƒS (!#›$) „ ‹ˆ˜’ˆ&“Ž’ …„—ˆ‰ˆ’ ‹ —€ˆ“…‘Œ„†‚' “ˆ‘Œ‘“‚' “Œ‰ˆ„ƒSƒˆ‘“ˆ„ƒ% (?!$) [4, 5].#…“…‘“ˆ “ˆ’‹™Œ“…Œ “€…˜“S†ˆ‹ “ˆ€S&Œ“…’ “ˆ‘Œ† ‹ “Œ€‹ŽŒ 4-6 “Œ‰Œ™% sˆ™Œ˜“… “S ”ˆ“Œ €S˜‹Œ€“‚ƒˆ† †™…-“…‘Œ„†ˆ† †S€ƒ…“Ž ‹S„†‚™…ƒS. !€… ‹ˆ‹™Œ‘Œ“…… “ˆ‘Œ† ‹ “Sƒˆ™ˆ‡…‘Œ„†…† “€ˆ/Œ„„ „“‚„ƒ’ ‡ˆ‰ … sˆ™ŒŒ “ˆ„™Œ †ˆ&-“ˆ‡ˆ ‰Œs'ƒS ˜Ssˆ™Œ‹S“…’ „‚*Œ„ƒ‹Œ““ˆ ‘S*Œ “Ss™'‰S-Œƒ„’ …„—ˆ‰ ‹ ?!$ “ˆ „€S‹“Œ“…' „ ‹S€…S“ƒˆ’ !#›$, †™…“…‘Œ„†S’ ’S“…”Œ„ƒS/…’ †ˆƒˆ€ˆ‡ˆ „ˆ‹“S‰SŒƒ “ˆ ‹€Œ-’Œ“… „ “S‘S™ˆ’ †ˆ&“ˆ‡ˆ ‹S„†‚™…ƒS [7]. • “ˆ„™Œ‰“…Œ ‰Œ-„’ƒ…™Œƒ…’ “ˆ’‹…™…„% „ˆˆs*Œ“…’ ˆ „Œ€…’— “Ss™'‰Œ“…† ˜Ssˆ™Œ‹S“…’ ‚ ‹˜€ˆ„™Ž— ™'‰Œ† … “S/…Œ“ƒˆ‹ “ˆ&…™ˆ‡ˆ ‹ˆ˜€S„ƒS, ‚†S˜Ž‹S'*…Œ “S sˆ™ŒŒ ƒ’&Œ™ˆŒ ƒŒ‘Œ“…Œ … —‚‰-‘…† “€ˆ‡“ˆ˜ ‡™ˆ’Œ€‚™ˆ“Œ”€…ƒS “€… ›• ‚ ‹˜€ˆ„™Ž—, ‘Œ’ ‚ ‰ŒƒŒ†. !ˆ ‰S““Ž’ “Œ†ˆƒˆ€Ž— S‹ƒˆ€ˆ‹, ‚ 90% ‹˜€ˆ„™Ž— “Œ”€…ƒ “€…ˆs€ŒƒSŒƒ —€ˆ“…‘Œ„†ˆŒ ƒŒ‘Œ“…Œ (!#›$) [14]. 1 ‹˜€ˆ„™Ž— ‘S„ƒˆƒS …„—ˆ‰S “Œ”€…ƒS “€… ›• ‹ ?!$ †ˆ™Œs™Œƒ„’ ˆƒ 10 ‰ˆ 30% [3, 6].1‹Œ™…‘Œ“…Œ ˜Ssˆ™Œ‹SŒ’ˆ„ƒ… ›• … ‘S„ƒˆƒŽ Œ‡ˆ “ˆ‘Œ‘-“Ž— “€ˆ’‹™Œ“…†, ƒ’&Œ„ƒ% ˆ„™ˆ&“Œ“…† “ˆ„ƒ†S“…™™’€ˆ-ƒˆ†„…‘Œ„†ˆ‡ˆ ‡™ˆ’Œ€‚™ˆ“Œ”€…ƒS ˆ“€Œ‰Œ™’'ƒ S†ƒ‚S™%-“ˆ„ƒ% …˜‚‘Œ“…’ +ƒˆ‡ˆ ˜Ssˆ™Œ‹S“…’. $Œ’“ˆ‡ˆ‘…„™Œ““Ž …„„™Œ‰ˆ‹S“…’, †S„S'*…Œ„’ +“…-‰Œ’…ˆ™ˆ‡…… ‡™ˆ’Œ€‚™ˆ“Œ”€…ƒS (›$), S„„ˆ/……€ˆ‹S““ˆ-‡ˆ „ ›•, S ‹ !€…sS††S™%Œ …„„™Œ‰ˆ‹S“…† ‰S““ˆ† “Sƒˆ™ˆ-‡…… “Œ “€ˆ‹ˆ‰…™ˆ„%. €ˆ’Œ ƒˆ‡ˆ, “S ˆ„“ˆ‹S“…… ˆ“ŽƒS •€†‚ƒ„†ˆ† “Œ”€ˆ™ˆ‡…‘Œ„†ˆ† †™…“…†… „†™S‰Ž‹SŒƒ„’ ‹“Œ‘Sƒ™Œ“…Œ ˆ ‹Ž„ˆ†ˆ† ‘S„ƒˆƒŒ ›• … !#›$ ‚ &…ƒŒ™Œ† !€…sS††S™%’, ˆ„ˆsŒ““ˆ ™…/ s‚€’ƒ„†ˆ† “S/…ˆ“S™%“ˆ„ƒ…. •ˆ˜’ˆ&“ˆ, +ƒˆ „‹’˜S“ˆ „ ‡Œ“Œƒ…‘Œ„†ˆ† “€Œ‰€S„“ˆ™ˆ&Œ“-“ˆ„ƒ%' † ˜Ssˆ™Œ‹S“…' ‚ ™…/ s‚€’ƒ„†ˆ† “ˆ“‚™’/……. DŒ™%' “S‘Œ‡ˆ …„„™Œ‰ˆ‹S“…’ ’‹…™ˆ„% ‚„ƒS“ˆ‹™Œ“…Œ €S„“€ˆ„ƒ€S“Œ““ˆ„ƒ…, ˆ„ˆsŒ““ˆ„ƒŒ† †™…“…‘Œ„†ˆ‡ˆ ƒŒ‘Œ-“…’ !#›$ ‹ !€…sS††S™%Œ, ‹†™'‘S’ …˜‚‘Œ“…Œ ‡Œ“Œƒ…†… “ˆ 1 †™S„„‚ HLA-†ˆ’“™Œ†„S ‹ €S˜“Ž— +ƒ“…‘Œ„†…— ‡€‚“-“S— sˆ™%“Ž—.

Topic: Vasculitis and related conditions
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences